Indirect treatment comparison of interventions for Neovascular (WET) age-related macular degeneration (WET AMD)

Abstract

A179according to Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores. METHODS: All patients who stayed on the same active treatment for 52 weeks were included. Active treatments were subcutaneous secukinumab 300 mg (n= 568) or 150 mg (n= 570) at weeks 0, 1, 2, 3, and 4, followed by dosing every 4 weeks, and subcutaneous etanercept 50 mg twice weekly for 12 weeks and then once weekly (n= 323). Total AUCs over the 52-week period by percentage of PASI-75/90/100 and DLQI-0/1 (no impact on patient quality of life) responders-measuring overall controlled disease time-were determined using all responder numbers at all scheduled visits. RESULTS: Total AUCs for patients who received secukinumab 300 and 150 mg, and etanercept, respectively, were: 3857.8, 3286.9, and 2628.1 (PASI-75); 3017.7, 2212.2, and 1531.8 (PASI-90); 1677.0, 978.9, and 452.5 (PASI-100); and 3029.8, 2492.2, and 1991.4 (DLQI-0/1). Total AUC ratios for secukinumab 300 and 150 mg, respectively, vs etanercept were 1.47 and 1.25 (PASI-75); 1.97 and 1.44 (PASI-90); 3.71 and 2.16 (PASI-100); and 1.52 and 1.25 (DLQI-0/1). Total AUC ratios for secukinumab 300 vs 150 mg were 1.17 (PASI-75), 1.36 (PASI-90), 1.71 (PASI-100), and 1.22 (DLQI-0/1). CONCLUSIONS: In patients with moderate-severe plaque psoriasis, greater AUCs by PASI-75/90/100 and DLQI-0/1 responders were achieved with secukinumab 300 mg, followed by secukinumab 150 mg and etanercept. This analysis suggests that secukinumab 300 mg resulted in the best overall disease control over time.OBJECTIVES: Assessment of how therapies achieve cumulative disease control over time is critical. In two phase III, 52-week trials (ERASURE and FIXTURE), secukinumab-a human, anti-interleukin-17A, monoclonal antibody-was an effective treatment for moderate-severe chronic plaque psoriasis. Pooled analysis of these trials was performed to explore the cumulative efficacy of secukinumab by assessing area-under-the-curve (AUC) of percentage of treatment responders

Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom

“…Patients in the IVAN trial had similar baseline characteristics to those used in the EXCITE study (mean age of 77.7); however, the mean BCVA in the study was slightly higher than that use in this analysis (mean BCVA of 61.4). The relative effectiveness of ranibizumab versus aflibercept was modelled using data from a NMA of randomized controlled trials [17] and was estimated for every month for 24 months using methods outlined in Ding and Fu [18]. The studies used to inform the NMA are provided in the Supplementary Material (Table S1).…”

“…BCVA change in the model was validated by comparing the mean BCVA change in each arm with the BCVA change observed in the original source (the IVAN trial [15] for BCVA progression in patients on ranibizumab, and the NMA [17] for the difference in BCVA between aflibercept and ranibizumab patients), over the first 24 months of treatment.…”